[Pharmacological Treatment of COVID-19: Narrative Review of the Working Group in Infectious Diseases and Sepsis (GTEIS) and the Working Groups in Transfusions and Blood Products (GTTH)]

Overview

Journal Med Intensiva

Specialty Critical Care

Date 2024 Apr 15

PMID 38620757

Authors

E Diaz

R Amezaga Menendez

P Vidal Cortes

M G Escapa

B Suberviola

A Serrano Lazaro

P Marcos Neira

M Quintana Diaz

M Catalan Gonzalez

Affiliations

Soon will be listed here.

Abstract

Infection by the SARS-CoV-2 virus, known as COVID-19 (COronaVIrus Disease-19) was initially detected in China in December 2019, and has subsequently spread rapidly throughout the world, to the point that on March 11 the World Health Organization (WHO) reported that the outbreak could be defined as a pandemic. COVID-19 disease ranges from mild flu-like episodes to other serious and even life-threatening conditions, mainly due to acute respiratory failure. These patients are frequently admitted to our Intensive Care Units in relation to acute respiratory distress syndrome. The lack of a treatment based on scientific evidence has led to the use of different management guidelines, in many cases with rapid changes in the applied protocols. Recent reviews in reputed journals have underscored the lack of proven therapies and the need for clinical trials to establish clear and objective treatment guidelines. The present study provides an update on the currently applied treatment, and intends to offer help in relation to daily care, without seeking to replace the protocols adopted in each individual center.

Citing Articles

Effects of Oxiris Therapy on Cytokine Elimination after a LPS Infusion-An Experimental Animal Study.

Kalenka A, Arens P, Mullenbach R, Weigand M, Brune M, Fiedler-Kalenka M Int J Mol Sci. 2024; 25(17).

PMID: 39273234 PMC: 11394842. DOI: 10.3390/ijms25179283.

A Comprehensive Review on Navigating the Neurological Landscape of COVID-19: Insights Into Etiopathogenesis and Clinical Management.

Chavhan R, Wanjari A, Kumar S, Acharya S, Rathod N, Reddy H Cureus. 2024; 16(5):e60079.

PMID: 38860093 PMC: 11163389. DOI: 10.7759/cureus.60079.

The use of complementary and traditional medicine for the treatment of patients with COVID-19: A systematic review.

Badanta B, Garcia M, Jimenez A, Lucchetti G, de Diego-Cordero R Explore (NY). 2023; 19(5):646-662.

PMID: 36828766 PMC: 9941070. DOI: 10.1016/j.explore.2023.02.005.

Current Treatments for COVID-19: Application of Supercritical Fluids in the Manufacturing of Oral and Pulmonary Formulations.

Ruiz H, Serrano D, Calvo L, Cabanas A Pharmaceutics. 2022; 14(11).

PMID: 36365198 PMC: 9697571. DOI: 10.3390/pharmaceutics14112380.

Impact of one year of pandemic on Spanish Intensive Care Units.

Vidal-Cortes P, Martin M, Diaz E, Bodi M, Igeno J, Garnacho-Montero J Rev Esp Quimioter. 2022; 35(4):392-400.

PMID: 35678324 PMC: 9333115. DOI: 10.37201/req/025.2022.

References

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

Cao W, Liu X, Bai T, Fan H, Hong K, Song H . High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019. Open Forum Infect Dis. 2020; 7(3):ofaa102. PMC: 7111600. DOI: 10.1093/ofid/ofaa102. View

Borba M, Val F, Sampaio V, Alexandre M, Melo G, Brito M . Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial. JAMA Netw Open. 2020; 3(4):e208857. DOI: 10.1001/jamanetworkopen.2020.8857. View

Villar J, Ferrando C, Martinez D, Ambros A, Munoz T, Soler J . Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020; 8(3):267-276. DOI: 10.1016/S2213-2600(19)30417-5. View

Middeldorp S, Coppens M, van Haaps T, Foppen M, Vlaar A, Muller M . Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020; 18(8):1995-2002. PMC: 7497052. DOI: 10.1111/jth.14888. View

Bikdeli B, Madhavan M, Jimenez D, Chuich T, Dreyfus I, Driggin E . COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-Up: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020; 75(23):2950-2973. PMC: 7164881. DOI: 10.1016/j.jacc.2020.04.031. View

Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A . Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020; 382(24):2327-2336. PMC: 7169476. DOI: 10.1056/NEJMoa2007016. View

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

Ye X, Luo Y, Xia S, Sun Q, Ding J, Zhou Y . Clinical efficacy of lopinavir/ritonavir in the treatment of Coronavirus disease 2019. Eur Rev Med Pharmacol Sci. 2020; 24(6):3390-3396. DOI: 10.26355/eurrev_202003_20706. View

10.

Zaragoza Garcia F, Ibarra Lorente M . [Interferon beta as a therapy for múltiple sclerosis]. Farm Hosp. 2003; 26(5):294-301. View

11.

Hung I, Lung K, Tso E, Liu R, Chung T, Chu M . Triple combination of interferon beta-1b, lopinavir-ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial. Lancet. 2020; 395(10238):1695-1704. PMC: 7211500. DOI: 10.1016/S0140-6736(20)31042-4. View

12.

Garcia Roche A, Diaz Lagares C, Elez E, Ferrer Roca R . Cytokine release syndrome. Reviewing a new entity in the intensive care unit. Med Intensiva (Engl Ed). 2019; 43(8):480-488. DOI: 10.1016/j.medin.2019.01.009. View

13.

Estella A, Garnacho-Montero J . [From empiricism to scientific evidence in antiviral treatment in severe cases of coronavirus infection in times of epidemic]. Med Intensiva (Engl Ed). 2020; 44(8):509-512. PMC: 7174180. DOI: 10.1016/j.medin.2020.04.009. View

14.

Zhang C, Wu Z, Li J, Zhao H, Wang G . Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents. 2020; 55(5):105954. PMC: 7118634. DOI: 10.1016/j.ijantimicag.2020.105954. View

15.

Alhazzani W, Moller M, Arabi Y, Loeb M, Gong M, Fan E . Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med. 2020; 46(5):854-887. PMC: 7101866. DOI: 10.1007/s00134-020-06022-5. View

16.

Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA. 2020; 323(16):1574-1581. PMC: 7136855. DOI: 10.1001/jama.2020.5394. View

17.

Chen J, Liu D, Liu L, Liu P, Xu Q, Xia L . [A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020; 49(2):215-219. PMC: 8800713. DOI: 10.3785/j.issn.1008-9292.2020.03.03. View

18.

Paranjpe I, Fuster V, Lala A, Russak A, Glicksberg B, Levin M . Association of Treatment Dose Anticoagulation With In-Hospital Survival Among Hospitalized Patients With COVID-19. J Am Coll Cardiol. 2020; 76(1):122-124. PMC: 7202841. DOI: 10.1016/j.jacc.2020.05.001. View

19.

Rascado Sedes P, Ballesteros Sanz M, Saera M, Carrasco Rodriguez-Rey L, Ortega A, Catalan Gonzalez M . [Contingency plan for the intensive care services for the COVID-19 pandemic]. Med Intensiva (Engl Ed). 2020; 44(6):363-370. PMC: 7180014. DOI: 10.1016/j.medin.2020.03.006. View

20.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View